Table 1 Characteristic of the patients of four major treatment regimes
From: Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006
HU | IFN-α(+Ara-C) | Imatinib | HSCT | |
|---|---|---|---|---|
Evaluable cases, no. | 78a | 203b | 217c | 28 |
Age, y | ||||
Median | 63 | 52 | 45.5 | 35 |
Range | 23-88 | 19-87 | 14-81 | 19-57 |
Male, no. (%) | 43(55.1) | 108(53.2) | 118(54.4) | 15(53.6) |
Female, no. (%) | 35(44.9) | 95(46.8) | 99(45.6) | 13(46.4) |
ECOG, no. (%) | ||||
0 | 62(79.5) | 168(82.8) | 175(80.7) | 24(85.7) |
1 | 13(16.7) | 31(15.2) | 35(16.1) | 3(10.7) |
2 | 3(3.8) | 4(2.0) | 7(3.2) | 1(3.6) |
Stage, no. (%) | ||||
CP | 70(89.7) | 184(90.7) | 154(71.0) | 21(75.0) |
AP | 6(7.7) | 12(5.9) | 25(11.5) | 4(14.3) |
BC | 2(2.6) | 7(3.4) | 38(17.5) | 3(10.7) |
Interval since diagnosis, mo | ||||
Median | 0.5 | 28 | 13 | 7.5 |
Range | 0-2 | 0-96 | 0-116 | 2-36 |
White-cell count (× 109/L) | ||||
Median | 25.6 | 31.2 | 28.9 | 21.2 |
Range | 2.2-667 | 7.5-540 | 11.2-760 | 9.0-350 |
Hemoglobin (× g/L) | ||||
Median | 120 | 123 | 115 | 128 |
Range | 68-177 | 56-170 | 66-188 | 70-175 |
Platelet count (× 109/L) | ||||
Median | 345 | 485 | 520 | 398 |
Range | 25-2520 | 21-3540 | 9-7050 | 45-2950 |
Peripheral-blood blasts, % (Range) | ||||
CP | 5(0-12) | 4.5(0-14) | 3(0-11) | 4(0-9) |
AP | 7(2-21) | 9(0-22) | 4(0-29) | 12(5-19) |
BC | 38(21-55) | 36(15-60) | 33(18-80) | 34(15-53) |
Peripheral-blood basophils, % (Range) | ||||
CP | 3(0-32) | 5(0-36) | 6(0-23) | 4(0-20) |
AP | 4(0-15) | 5(0-10) | 3(0-11) | 5(1-9) |
BC | 7(5-9) | 4(0-12) | 6(0-18) | 9(3-15) |
Splenomegaly, no. (%) | ||||
Any splenomegaly | 21(26.9) | 61(30.0) | 75(34.6) | 3(10.7) |
At least 10 cm | 8(10.3) | 28(13.8) | 32(14.7) | 1(3.6) |